Lamb, Harriet M.; Wiseman, Lynda R. - In: PharmacoEconomics 14 (1998) 4, pp. 447-459
Advanced breast cancer has a poor prognosis (median duration of survival about 2 years); thus, treatment options are largely palliative. Recent studies with the taxoids docetaxel and paclitaxel suggest that these agents are effective second-line therapy in patients with metastatic breast cancer....